- Home
- OPTN
OPTN
OptiNose Inc.
as 03-25-2025 4:00pm EST
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | YARDLEY |
| Market Cap: | 55.4M | IPO Year: | 2017 |
| Target Price: | $9.00 | AVG Volume (30 days): | 155.2K |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.82 - $23.55 | Next Earning Date: | 05-13-2025 |
| Revenue: | $75,672,000 | Revenue Growth: | 5.13% |
| Revenue Growth (this year): | 13.42% | Revenue Growth (next year): | 38.54% |
Stock Insider Trading Activity of OptiNose Inc. (OPTN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Marino Michael F III | OPTN | Chief Legal Officer & Corp Sec | Mar 18 '25 | Sell | $5.61 | 246 | $1,380.06 | 55,038 | |
| Mahmoud Ramy A | OPTN | Chief Executive Officer | Mar 4 '25 | Sell | $5.29 | 6,376 | $33,729.04 | 126,931 | |
| Spence Paul Jr. | OPTN | Chief Commercial Officer | Mar 4 '25 | Sell | $5.29 | 1,223 | $6,469.67 | 32,647 |
Latest OptiNose Inc. News
OPTN Breaking Stock News: Dive into OPTN Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Wall Street Analysts Believe OptiNose (OPTN) Could Rally 143.06%: Here's is How to Trade
Zacks
4 days ago
OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek
GuruFocus.com
4 days ago
Earnings To Watch: OptiNose Inc (OPTN) Reports Q4 2024 Result
Insider Monkey
4 days ago
Why OptiNose Inc. (OPTN) Surged On Thursday?
MT Newswires
5 days ago
Top Midday Gainers
MT Newswires
5 days ago
Top Premarket Gainers
MT Newswires
5 days ago
OptiNose Surges Premarket Following Acquisition Agreement With Paratek Pharmaceuticals for Up to $330 Million
GlobeNewswire
6 days ago
Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call
Compare OPTN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OPTN OptiNose Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.